{
    "info": {
        "nct_id": "NCT04631744",
        "official_title": "Open Label Phase II Trial of Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) and Known Amplifications or Activating Mutations in Gene Targets of Cabozantinib or Liver Metastases Who Have Received Prior Anti-Androgen Therapy",
        "inclusion_criteria": "Inclusion Criteria\n\n1. Age >18 years.\n2. Documented histological or cytological diagnosis of prostate carcinoma.\n3. Evidence of metastatic PC on imaging (bone scan and/or CT/MRI scan)\n\n   - Patients with liver metastases must have biopsy proven evidence of metastatic prostate cancer in the liver.\n4. Agree to undergo a biopsy of at least one metastatic site or primary prostate prior to beginning therapy. Adequate archival metastatic tissue can be used if available in lieu of a biopsy if done when patient had CRPC and within 6 months of the start of treatment.\n5. Agree to undergo a biopsy of at least one metastatic site or primary prostate after 3 weeks of therapy (biopsy must be between day 21 and day 24 of treatment). Re-biopsy of same pre-treatment biopsy soft tissue site especially liver metastases is preferred.\n6. Serum testosterone level less than 50 ng/dl. Subjects without prior orchiectomy must be currently taking and willing to continue luteinizing hormone-releasing hormone (LHRH) analogue (agonist or antagonist) therapy until permanent discontinuation of study treatment.\n7. Documented progressive metastatic CRPC based on at least one of the following criteria:\n\n   * PSA progression according to Prostate Cancer Working Group 3 (PCWG3) criteria\n   * Objective radiographic progression, according to PCWG3 criteria\n8. ECOG performance status of 0-1\n9. Recovery to baseline or ≤ Grade 1 CTCAE v4 from toxicities related to any prior treatments, unless specified below or AE(s) are clinically nonsignificant and/or stable on supportive therapy.\n10. Adequate organ and marrow function, based upon meeting all of the following laboratory criteria within 14 days before first dose of study treatment:\n\n    * Absolute neutrophil count (ANC) ≥ 1500/mm^3 (≥ 1.5 GI/L) without granulocyte colony-stimulating factor support\n    * White blood cell count ≥ 2500/mm^3 (≥ 2.5 GI/L)\n    * Platelets ≥ 100,000/mm^3 (≥ 100 GI/L) without transfusion\n    * Hemoglobin ≥ 9 g/dL (≥ 90 g/L)\n    * Total bilirubin ≤ 1.5 x ULN (for subjects with Gilbert's disease ≤ 3 x ULN)\n    * Serum albumin ≥ 2.8 g/dl\n    * Serum creatinine ≤ 2.0 x ULN or calculated creatinine clearance ≥ 30 mL/min (≥ 0.5 mL/sec) using the Cockcroft-Gault equation:\n    * If urine dipstick is positive, then: Urine protein/creatinine ratio (UPCR) ≤ 1 mg/mg (≤ 113.2 mg/mmol)\n11. Patients without liver metastases must have evidence of amplification or activating mutation of selected targets of cabozantinib (including MET, KIT, RET, VEGFR-1, VEGFR-2, VEGFR-3, FLT3, AXL, TRKB, or TIE2) by at least one of the following:\n\n    * DNA sequencing of metastatic tumor biopsy specimen or cfDNA test\n    * RNA sequencing of metastatic tumor biopsy specimen\n    * Commercial cell-free DNA assay\n    * Overexpression by IHC on metastatic tumor biopsy specimen\n12. Sexually active fertile subjects and their partners must agree to use medically accepted methods of contraception (e.g., barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the course of the study and for 4 months after the last dose of study treatment\n13. Capable of understanding and complying with the protocol requirements and must have signed the informed consent document\n\nExclusion Criteria\n\n1. Prior treatment with cabozantinib\n2. Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before first dose of study treatment.\n3. Receipt of any type of cytotoxic, biologic or other systemic anticancer therapy (including investigational) except agents to maintain castrate status within 4 weeks before first dose of study treatment. Antiresportive bone agents are also allowed.\n4. Subject has received abiraterone acetate or enzalutamide within 2 weeks before enrollment.\n5. Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 4 weeks before first dose of study treatment. Systemic treatment with radionuclides within 6 weeks before the first dose of study treatment. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible.\n6. Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks prior to first dose of study treatment after radiotherapy or at least 4 weeks prior to first dose of study treatment after major surgery (e.g., removal or biopsy of brain metastasis). Subjects must have complete wound healing from major surgery or minor surgery before first dose of study treatment. Eligible subjects must be neurologically asymptomatic and without corticosteroid treatment for neurological indications at the time of first dose of study treatment.\n7. Concomitant anticoagulation with coumarin agents (e.g., warfarin), direct thrombin inhibitors (e.g., dabigatran), direct factor Xa inhibitor betrixaban, or platelet inhibitors (e.g., clopidogrel). Allowed anticoagulants are the following:\n\n   * Prophylactic use of low-dose aspirin for cardio-protection (per local applicable guidelines) and low-dose low molecular weight heparins (LMWH).\n   * Therapeutic doses of LMWH or anticoagulation with direct factor Xa inhibitors rivaroxaban, edoxaban, or apixaban in subjects without known brain metastases who are on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment without clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor.\n8. The subject has prothrombin time (PT)/INR or partial thromboplastin time (PTT) test ≥ 1.3 x the laboratory ULN within 14 days before the first dose of study treatment.\n9. The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:\n\n   * Cardiovascular disorders:\n\n     * Congestive heart failure New York Heart Association Class 3 or 4, unstable angina pectoris, serious cardiac arrhythmias.\n     * Uncontrolled hypertension defined as sustained blood pressure (BP) >140 mm Hg systolic or >90 mm Hg diastolic despite optimal antihypertensive treatment.\n     * Stroke (including transient ischemic attack [TIA]), myocardial infarction (MI), or other ischemic event, or thromboembolic event (e.g. deep venous thrombosis, pulmonary embolism) within 6 months before first dose.\n   * Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation:\n\n     * The subject has evidence of tumor invading the GI tract, active peptic ulcer disease, inflammatory bowel disease (e.g., Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, acute pancreatitis, acute obstruction of the pancreatic duct or common bile duct, or gastric outlet obstruction.\n     * Abdominal fistula, GI perforation, bowel obstruction, or intra-abdominal abscess within 6 months before first dose.\n\n   Note: Complete healing of an intra-abdominal abscess must be confirmed before first dose.\n   * Clinically significant hematuria, hematemesis, or hemoptysis of > 0.5 teaspoon (2.5 mL) of red blood, or other history of significant bleeding (e.g., pulmonary hemorrhage) within 12 weeks before first dose.\n   * Cavitating pulmonary lesion(s) or known endotracheal or endobronchial disease manifestation.\n   * Lesions invading or encasing any major blood vessels. Subjects with lesions invading the intrahepatic vasculature, including portal vein, hepatic vein, and hepatic artery, are eligible.\n   * Other clinically significant disorders that would preclude safe study participation.\n\n     * Serious non-healing wound/ulcer/bone fracture.\n     * Uncompensated/symptomatic hypothyroidism.\n     * Moderate to severe hepatic impairment (Child-Pugh B or C).\n10. Major surgery (e.g., GI surgery, removal or biopsy of brain metastasis) within 8 weeks before first dose of study treatment. Complete wound healing from major surgery must have occurred 1 month before first dose and from minor surgery (e.g. simple excision, tooth extraction) at least 10 days before first dose. Subjects with clinically relevant ongoing complications from prior surgery are not eligible.\n11. Corrected QT interval calculated by the Fridericia formula (QTcF) > 500 ms per electrocardiogram (ECG) within 28 days before first dose of study treatment [add reference for Fridericia formula].\n\n    Note: If a single ECG shows a QTcF with an absolute value > 500 ms, two additional ECGs at intervals of approximately 3 min must be performed within 30 min after the initial ECG, and the average of these three consecutive results for QTcF will be used to determine eligibility.\n12. Inability to swallow tablets.\n13. Previously identified allergy or hypersensitivity to components of the study treatment formulations.\n14. Diagnosis of another malignancy within 2 years before first dose of study treatment, except for superficial skin cancers, or localized, low-grade tumors deemed cured and not treated with systemic therapy.\n\nMolecular Eligibility\n\nTo be eligible, a patient's tumor must have evidence of gene amplification, an activating mutation, or overexpression of one of the following genes: MET, KIT, RET, VEGFR-1, VEGFR-2, VEGFR-3, FLT3, AXL, TRKB, or TIE2. Eligibility can be met via the following diagnostic tests:\n\n1. DNA sequencing of a metastatic tumor biopsy specimen showing gene amplification or activating mutation using a CLIA-certified assay. Tumor tissue samples must have been collected within 6 months of enrollment.\n2. Protein overexpression in a metastatic tumor biopsy specimen determined by immunohistochemistry (IHC) showing 2+ or 3+ protein expression using a CLIA-certified assay.These include common in-house KIT and commercial reference labs for panTRK (e.g. NeoGenomics) and cMET (e.g. NeoGenomics, Caris, Mayo Clinic).\n3. CLIA-certified commercial cell free DNA assay reporting gene amplification or activating mutation within 3 months of enrollment.\n\n   * For the Guardant360 Liquid Biopsy amplification must be at least (++) or (+++) for to meet eligibility.\n   * For the FoundationOneLiquid assay, amplification will be eligible. Reports that have an \"equivocal\" or \"subclonal\" designation will not be eligible.\n4. Any non-CLIA certified assay such as RNA expression profiling of a metastatic tumor biopsy specimen showing overexpression must be confirmed by a CLIA-certified assay (i.e., immunohistochemistry showing 2+ or 3+ protein expression)\n\nPatients who do not meet molecular eligibility criteria will be allowed to enroll if they have liver metastases that meet RECIST criteria for measurable disease. Patients with prostate adenocarcinoma or Neuroendocrine prostate cancer (NEPC) will be allowed to enroll.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years\nMust have maximum age of 99 Years",
        "exclusion_criteria": "",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Total bilirubin ≤ 1.5 x ULN (for subjects with Gilbert's disease ≤ 3 x ULN)",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin ≤ 1.5 x ULN (for subjects with Gilbert's disease ≤ 3 x ULN)",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 1.5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "for subjects with Gilbert's disease ≤ 3 x ULN",
                    "criterion": "total bilirubin in subjects with Gilbert's disease",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prophylactic use of low-dose aspirin for cardio-protection (per local applicable guidelines) and low-dose low molecular weight heparins (LMWH).",
            "criterions": [
                {
                    "exact_snippets": "Prophylactic use of low-dose aspirin for cardio-protection (per local applicable guidelines)",
                    "criterion": "aspirin use",
                    "requirements": [
                        {
                            "requirement_type": "purpose",
                            "expected_value": "prophylactic"
                        },
                        {
                            "requirement_type": "dose",
                            "expected_value": "low-dose"
                        },
                        {
                            "requirement_type": "indication",
                            "expected_value": "cardio-protection"
                        }
                    ]
                },
                {
                    "exact_snippets": "low-dose low molecular weight heparins (LMWH)",
                    "criterion": "low molecular weight heparin (LMWH) use",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": "low-dose"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Age >18 years.",
            "criterions": [
                {
                    "exact_snippets": "Age >18 years.",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Documented histological or cytological diagnosis of prostate carcinoma.",
            "criterions": [
                {
                    "exact_snippets": "Documented histological or cytological diagnosis of prostate carcinoma",
                    "criterion": "prostate carcinoma diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis_method",
                            "expected_value": [
                                "histological",
                                "cytological"
                            ]
                        },
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Evidence of metastatic PC on imaging (bone scan and/or CT/MRI scan)",
            "criterions": [
                {
                    "exact_snippets": "Evidence of metastatic PC on imaging (bone scan and/or CT/MRI scan)",
                    "criterion": "metastatic prostate cancer (PC)",
                    "requirements": [
                        {
                            "requirement_type": "evidence_on_imaging",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "bone scan and/or CT/MRI scan",
                    "criterion": "imaging modality",
                    "requirements": [
                        {
                            "requirement_type": "modality",
                            "expected_value": [
                                "bone scan",
                                "CT scan",
                                "MRI scan"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "- Patients with liver metastases must have biopsy proven evidence of metastatic prostate cancer in the liver.",
            "criterions": [
                {
                    "exact_snippets": "Patients with liver metastases",
                    "criterion": "liver metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "biopsy proven evidence of metastatic prostate cancer in the liver",
                    "criterion": "metastatic prostate cancer in the liver",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "biopsy proven evidence"
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Agree to undergo a biopsy of at least one metastatic site or primary prostate after 3 weeks of therapy (biopsy must be between day 21 and day 24 of treatment). Re-biopsy of same pre-treatment biopsy soft tissue site especially liver metastases is preferred.",
            "criterions": [
                {
                    "exact_snippets": "Agree to undergo a biopsy of at least one metastatic site or primary prostate after 3 weeks of therapy (biopsy must be between day 21 and day 24 of treatment)",
                    "criterion": "biopsy of metastatic site or primary prostate",
                    "requirements": [
                        {
                            "requirement_type": "agreement to undergo procedure",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "number of sites",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "site"
                            }
                        },
                        {
                            "requirement_type": "timing after therapy",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 21,
                                        "unit": "days"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 24,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Re-biopsy of same pre-treatment biopsy soft tissue site especially liver metastases is preferred",
                    "criterion": "re-biopsy of pre-treatment soft tissue site (especially liver metastases)",
                    "requirements": [
                        {
                            "requirement_type": "preference",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Documented progressive metastatic CRPC based on at least one of the following criteria:",
            "criterions": [
                {
                    "exact_snippets": "Documented progressive metastatic CRPC",
                    "criterion": "progressive metastatic castration-resistant prostate cancer (CRPC)",
                    "requirements": [
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "progression",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "metastatic",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "castration-resistant",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "prostate cancer",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PSA progression according to Prostate Cancer Working Group 3 (PCWG3) criteria",
            "criterions": [
                {
                    "exact_snippets": "PSA progression according to Prostate Cancer Working Group 3 (PCWG3) criteria",
                    "criterion": "PSA progression",
                    "requirements": [
                        {
                            "requirement_type": "meets definition",
                            "expected_value": "according to Prostate Cancer Working Group 3 (PCWG3) criteria"
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Serum testosterone level less than 50 ng/dl. Subjects without prior orchiectomy must be currently taking and willing to continue luteinizing hormone-releasing hormone (LHRH) analogue (agonist or antagonist) therapy until permanent discontinuation of study treatment.",
            "criterions": [
                {
                    "exact_snippets": "Serum testosterone level less than 50 ng/dl",
                    "criterion": "serum testosterone level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 50,
                                "unit": "ng/dl"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects without prior orchiectomy must be currently taking ... luteinizing hormone-releasing hormone (LHRH) analogue (agonist or antagonist) therapy",
                    "criterion": "LHRH analogue therapy",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects without prior orchiectomy ... willing to continue luteinizing hormone-releasing hormone (LHRH) analogue (agonist or antagonist) therapy until permanent discontinuation of study treatment",
                    "criterion": "LHRH analogue therapy",
                    "requirements": [
                        {
                            "requirement_type": "willingness to continue",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Objective radiographic progression, according to PCWG3 criteria",
            "criterions": [
                {
                    "exact_snippets": "Objective radiographic progression",
                    "criterion": "radiographic progression",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "objectivity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "according to PCWG3 criteria",
                    "criterion": "PCWG3 criteria for progression",
                    "requirements": [
                        {
                            "requirement_type": "adherence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Agree to undergo a biopsy of at least one metastatic site or primary prostate prior to beginning therapy. Adequate archival metastatic tissue can be used if available in lieu of a biopsy if done when patient had CRPC and within 6 months of the start of treatment.",
            "criterions": [
                {
                    "exact_snippets": "Agree to undergo a biopsy of at least one metastatic site or primary prostate prior to beginning therapy.",
                    "criterion": "biopsy of metastatic site or primary prostate",
                    "requirements": [
                        {
                            "requirement_type": "agreement to undergo procedure",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "number of sites",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "site"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to beginning therapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate archival metastatic tissue can be used if available in lieu of a biopsy if done when patient had CRPC and within 6 months of the start of treatment.",
                    "criterion": "archival metastatic tissue",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing of collection",
                            "expected_value": "within 6 months of the start of treatment"
                        },
                        {
                            "requirement_type": "disease state at collection",
                            "expected_value": "CRPC"
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. ECOG performance status of 0-1",
            "criterions": [
                {
                    "exact_snippets": "ECOG performance status of 0-1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Adequate organ and marrow function, based upon meeting all of the following laboratory criteria within 14 days before first dose of study treatment:",
            "criterions": [
                {
                    "exact_snippets": "Adequate organ and marrow function",
                    "criterion": "organ and marrow function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Recovery to baseline or ≤ Grade 1 CTCAE v4 from toxicities related to any prior treatments, unless specified below or AE(s) are clinically nonsignificant and/or stable on supportive therapy.",
            "criterions": [
                {
                    "exact_snippets": "Recovery to baseline or ≤ Grade 1 CTCAE v4 from toxicities related to any prior treatments",
                    "criterion": "toxicities related to any prior treatments",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "CTCAE v4 grade"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "recovery_status",
                            "expected_value": [
                                "recovery to baseline"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "unless specified below or AE(s) are clinically nonsignificant and/or stable on supportive therapy",
                    "criterion": "adverse events (AEs) related to prior treatments",
                    "requirements": [
                        {
                            "requirement_type": "clinical_significance",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "stability_on_supportive_therapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count (ANC) ≥ 1500/mm^3 (≥ 1.5 GI/L) without granulocyte colony-stimulating factor support",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) ≥ 1500/mm^3 (≥ 1.5 GI/L)",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "mm^3"
                            }
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.5,
                                "unit": "GI/L"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "without granulocyte colony-stimulating factor support",
                    "criterion": "granulocyte colony-stimulating factor support",
                    "requirements": [
                        {
                            "requirement_type": "support",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* White blood cell count ≥ 2500/mm^3 (≥ 2.5 GI/L)",
            "criterions": [
                {
                    "exact_snippets": "White blood cell count ≥ 2500/mm^3 (≥ 2.5 GI/L)",
                    "criterion": "white blood cell count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2500,
                                "unit": "mm^3"
                            }
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2.5,
                                "unit": "GI/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelets ≥ 100,000/mm^3 (≥ 100 GI/L) without transfusion",
            "criterions": [
                {
                    "exact_snippets": "Platelets ≥ 100,000/mm^3 (≥ 100 GI/L) without transfusion",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "mm^3"
                            }
                        },
                        {
                            "requirement_type": "transfusion",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin ≥ 9 g/dL (≥ 90 g/L)",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin ≥ 9 g/dL (≥ 90 g/L)",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9,
                                "unit": "g/dL"
                            }
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 90,
                                "unit": "g/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum albumin ≥ 2.8 g/dl",
            "criterions": [
                {
                    "exact_snippets": "Serum albumin ≥ 2.8 g/dl",
                    "criterion": "serum albumin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2.8,
                                "unit": "g/dl"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* If urine dipstick is positive, then: Urine protein/creatinine ratio (UPCR) ≤ 1 mg/mg (≤ 113.2 mg/mmol)",
            "criterions": [
                {
                    "exact_snippets": "urine dipstick is positive",
                    "criterion": "urine dipstick result",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "Urine protein/creatinine ratio (UPCR) ≤ 1 mg/mg (≤ 113.2 mg/mmol)",
                    "criterion": "urine protein/creatinine ratio (UPCR)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "mg/mg"
                            }
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 113.2,
                                "unit": "mg/mmol"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum creatinine ≤ 2.0 x ULN or calculated creatinine clearance ≥ 30 mL/min (≥ 0.5 mL/sec) using the Cockcroft-Gault equation:",
            "criterions": [
                {
                    "exact_snippets": "Serum creatinine ≤ 2.0 x ULN",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.0,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "calculated creatinine clearance ≥ 30 mL/min (≥ 0.5 mL/sec) using the Cockcroft-Gault equation",
                    "criterion": "calculated creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "mL/min"
                            }
                        },
                        {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockcroft-Gault equation"
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Patients without liver metastases must have evidence of amplification or activating mutation of selected targets of cabozantinib (including MET, KIT, RET, VEGFR-1, VEGFR-2, VEGFR-3, FLT3, AXL, TRKB, or TIE2) by at least one of the following:",
            "criterions": [
                {
                    "exact_snippets": "Patients without liver metastases",
                    "criterion": "liver metastases",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "evidence of amplification or activating mutation of selected targets of cabozantinib (including MET, KIT, RET, VEGFR-1, VEGFR-2, VEGFR-3, FLT3, AXL, TRKB, or TIE2)",
                    "criterion": "amplification or activating mutation of selected targets of cabozantinib",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "target_genes",
                            "expected_value": [
                                "MET",
                                "KIT",
                                "RET",
                                "VEGFR-1",
                                "VEGFR-2",
                                "VEGFR-3",
                                "FLT3",
                                "AXL",
                                "TRKB",
                                "TIE2"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* RNA sequencing of metastatic tumor biopsy specimen",
            "criterions": [
                {
                    "exact_snippets": "RNA sequencing of metastatic tumor biopsy specimen",
                    "criterion": "metastatic tumor biopsy specimen",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "RNA sequencing of metastatic tumor biopsy specimen",
                    "criterion": "RNA sequencing",
                    "requirements": [
                        {
                            "requirement_type": "performed_on",
                            "expected_value": "metastatic tumor biopsy specimen"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Commercial cell-free DNA assay",
            "criterions": [
                {
                    "exact_snippets": "Commercial cell-free DNA assay",
                    "criterion": "cell-free DNA assay",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": "commercial"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Overexpression by IHC on metastatic tumor biopsy specimen",
            "criterions": [
                {
                    "exact_snippets": "Overexpression by IHC on metastatic tumor biopsy specimen",
                    "criterion": "protein expression in metastatic tumor biopsy",
                    "requirements": [
                        {
                            "requirement_type": "expression level",
                            "expected_value": "overexpression"
                        },
                        {
                            "requirement_type": "detection method",
                            "expected_value": "IHC"
                        },
                        {
                            "requirement_type": "specimen type",
                            "expected_value": "metastatic tumor biopsy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Exclusion Criteria",
            "criterions": [
                {
                    "exact_snippets": "Exclusion Criteria",
                    "criterion": "exclusion criteria",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": "This is a section header and does not specify any patient attribute or condition."
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. Capable of understanding and complying with the protocol requirements and must have signed the informed consent document",
            "criterions": [
                {
                    "exact_snippets": "Capable of understanding and complying with the protocol requirements",
                    "criterion": "ability to understand and comply with protocol requirements",
                    "requirements": [
                        {
                            "requirement_type": "capability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must have signed the informed consent document",
                    "criterion": "informed consent document",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Subject has received abiraterone acetate or enzalutamide within 2 weeks before enrollment.",
            "criterions": [
                {
                    "exact_snippets": "Subject has received abiraterone acetate ... within 2 weeks before enrollment.",
                    "criterion": "abiraterone acetate administration",
                    "requirements": [
                        {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Subject has received ... enzalutamide within 2 weeks before enrollment.",
                    "criterion": "enzalutamide administration",
                    "requirements": [
                        {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Sexually active fertile subjects and their partners must agree to use medically accepted methods of contraception (e.g., barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the course of the study and for 4 months after the last dose of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Sexually active fertile subjects and their partners must agree to use medically accepted methods of contraception (e.g., barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the course of the study and for 4 months after the last dose of study treatment",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "contraception method",
                            "expected_value": [
                                "medically accepted methods",
                                "barrier methods",
                                "male condom",
                                "female condom",
                                "diaphragm with spermicidal gel"
                            ]
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "during the course of the study and for 4 months after the last dose of study treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Concomitant anticoagulation with coumarin agents (e.g., warfarin), direct thrombin inhibitors (e.g., dabigatran), direct factor Xa inhibitor betrixaban, or platelet inhibitors (e.g., clopidogrel). Allowed anticoagulants are the following:",
            "criterions": [
                {
                    "exact_snippets": "Concomitant anticoagulation with coumarin agents (e.g., warfarin)",
                    "criterion": "concomitant anticoagulation with coumarin agents",
                    "requirements": [
                        {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Concomitant anticoagulation with ... direct thrombin inhibitors (e.g., dabigatran)",
                    "criterion": "concomitant anticoagulation with direct thrombin inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Concomitant anticoagulation with ... direct factor Xa inhibitor betrixaban",
                    "criterion": "concomitant anticoagulation with direct factor Xa inhibitor betrixaban",
                    "requirements": [
                        {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Concomitant anticoagulation with ... platelet inhibitors (e.g., clopidogrel)",
                    "criterion": "concomitant anticoagulation with platelet inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Receipt of any type of cytotoxic, biologic or other systemic anticancer therapy (including investigational) except agents to maintain castrate status within 4 weeks before first dose of study treatment. Antiresportive bone agents are also allowed.",
            "criterions": [
                {
                    "exact_snippets": "Receipt of any type of cytotoxic, biologic or other systemic anticancer therapy (including investigational) ... within 4 weeks before first dose of study treatment",
                    "criterion": "receipt of systemic anticancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "except agents to maintain castrate status ... Antiresportive bone agents are also allowed",
                    "criterion": "use of agents to maintain castrate status or antiresorptive bone agents",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Prior treatment with cabozantinib",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with cabozantinib",
                    "criterion": "cabozantinib treatment",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before first dose of study treatment.",
            "criterions": [
                {
                    "exact_snippets": "Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before first dose of study treatment.",
                    "criterion": "small molecule kinase inhibitor receipt",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks before first dose of study treatment"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Therapeutic doses of LMWH or anticoagulation with direct factor Xa inhibitors rivaroxaban, edoxaban, or apixaban in subjects without known brain metastases who are on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment without clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor.",
            "criterions": [
                {
                    "exact_snippets": "Therapeutic doses of LMWH or anticoagulation with direct factor Xa inhibitors rivaroxaban, edoxaban, or apixaban",
                    "criterion": "anticoagulation regimen",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "therapeutic doses of LMWH",
                                "direct factor Xa inhibitors rivaroxaban",
                                "edoxaban",
                                "apixaban"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "in subjects without known brain metastases",
                    "criterion": "brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment",
                    "criterion": "anticoagulant dose stability",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "week"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "without clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor",
                    "criterion": "clinically significant hemorrhagic complications",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. The subject has prothrombin time (PT)/INR or partial thromboplastin time (PTT) test ≥ 1.3 x the laboratory ULN within 14 days before the first dose of study treatment.",
            "criterions": [
                {
                    "exact_snippets": "prothrombin time (PT)/INR ... ≥ 1.3 x the laboratory ULN within 14 days before the first dose of study treatment",
                    "criterion": "prothrombin time (PT)/INR",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "partial thromboplastin time (PTT) test ≥ 1.3 x the laboratory ULN within 14 days before the first dose of study treatment",
                    "criterion": "partial thromboplastin time (PTT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation:",
            "criterions": [
                {
                    "exact_snippets": "Gastrointestinal (GI) disorders",
                    "criterion": "gastrointestinal disorders",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "associated with a high risk of perforation",
                    "criterion": "risk of gastrointestinal perforation",
                    "requirements": [
                        {
                            "requirement_type": "risk",
                            "expected_value": "high"
                        }
                    ]
                },
                {
                    "exact_snippets": "associated with a high risk of ... fistula formation",
                    "criterion": "risk of gastrointestinal fistula formation",
                    "requirements": [
                        {
                            "requirement_type": "risk",
                            "expected_value": "high"
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:",
            "criterions": [
                {
                    "exact_snippets": "uncontrolled, significant intercurrent or recent illness",
                    "criterion": "intercurrent or recent illness",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Cavitating pulmonary lesion(s) or known endotracheal or endobronchial disease manifestation.",
            "criterions": [
                {
                    "exact_snippets": "Cavitating pulmonary lesion(s)",
                    "criterion": "pulmonary lesion",
                    "requirements": [
                        {
                            "requirement_type": "cavitation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known endotracheal or endobronchial disease manifestation",
                    "criterion": "endotracheal or endobronchial disease manifestation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Other clinically significant disorders that would preclude safe study participation.",
            "criterions": [
                {
                    "exact_snippets": "Other clinically significant disorders that would preclude safe study participation.",
                    "criterion": "clinically significant disorders",
                    "requirements": [
                        {
                            "requirement_type": "impact on study participation",
                            "expected_value": "would preclude safe study participation"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Note: Complete healing of an intra-abdominal abscess must be confirmed before first dose.",
            "criterions": [
                {
                    "exact_snippets": "Complete healing of an intra-abdominal abscess must be confirmed before first dose.",
                    "criterion": "intra-abdominal abscess",
                    "requirements": [
                        {
                            "requirement_type": "healing_status",
                            "expected_value": "complete"
                        },
                        {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Cardiovascular disorders:",
            "criterions": [
                {
                    "exact_snippets": "Cardiovascular disorders",
                    "criterion": "cardiovascular disorders",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Congestive heart failure New York Heart Association Class 3 or 4, unstable angina pectoris, serious cardiac arrhythmias.",
            "criterions": [
                {
                    "exact_snippets": "Congestive heart failure New York Heart Association Class 3 or 4",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "NYHA class",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": "NYHA class"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable angina pectoris",
                    "criterion": "angina pectoris",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": "unstable"
                        }
                    ]
                },
                {
                    "exact_snippets": "serious cardiac arrhythmias",
                    "criterion": "cardiac arrhythmias",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "serious"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncompensated/symptomatic hypothyroidism.",
            "criterions": [
                {
                    "exact_snippets": "Uncompensated/symptomatic hypothyroidism",
                    "criterion": "hypothyroidism",
                    "requirements": [
                        {
                            "requirement_type": "compensation status",
                            "expected_value": "uncompensated"
                        },
                        {
                            "requirement_type": "symptom status",
                            "expected_value": "symptomatic"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Moderate to severe hepatic impairment (Child-Pugh B or C).",
            "criterions": [
                {
                    "exact_snippets": "Moderate to severe hepatic impairment (Child-Pugh B or C)",
                    "criterion": "hepatic impairment",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": [
                                "moderate",
                                "severe"
                            ]
                        },
                        {
                            "requirement_type": "Child-Pugh classification",
                            "expected_value": [
                                "B",
                                "C"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Inability to swallow tablets.",
            "criterions": [
                {
                    "exact_snippets": "Inability to swallow tablets",
                    "criterion": "ability to swallow tablets",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Lesions invading or encasing any major blood vessels. Subjects with lesions invading the intrahepatic vasculature, including portal vein, hepatic vein, and hepatic artery, are eligible.",
            "criterions": [
                {
                    "exact_snippets": "Lesions invading or encasing any major blood vessels.",
                    "criterion": "lesions invading or encasing major blood vessels",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects with lesions invading the intrahepatic vasculature, including portal vein, hepatic vein, and hepatic artery, are eligible.",
                    "criterion": "lesions invading intrahepatic vasculature (portal vein, hepatic vein, hepatic artery)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled hypertension defined as sustained blood pressure (BP) >140 mm Hg systolic or >90 mm Hg diastolic despite optimal antihypertensive treatment.",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled hypertension defined as sustained blood pressure (BP) >140 mm Hg systolic or >90 mm Hg diastolic despite optimal antihypertensive treatment.",
                    "criterion": "blood pressure (BP) systolic",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 140,
                                "unit": "mm Hg"
                            }
                        },
                        {
                            "requirement_type": "sustained",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "despite optimal antihypertensive treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Uncontrolled hypertension defined as sustained blood pressure (BP) >140 mm Hg systolic or >90 mm Hg diastolic despite optimal antihypertensive treatment.",
                    "criterion": "blood pressure (BP) diastolic",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 90,
                                "unit": "mm Hg"
                            }
                        },
                        {
                            "requirement_type": "sustained",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "despite optimal antihypertensive treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Molecular Eligibility",
            "criterions": [
                {
                    "exact_snippets": "Molecular Eligibility",
                    "criterion": "molecular eligibility",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. Previously identified allergy or hypersensitivity to components of the study treatment formulations.",
            "criterions": [
                {
                    "exact_snippets": "Previously identified allergy or hypersensitivity to components of the study treatment formulations.",
                    "criterion": "allergy or hypersensitivity to components of the study treatment formulations",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "previously identified"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Note: If a single ECG shows a QTcF with an absolute value > 500 ms, two additional ECGs at intervals of approximately 3 min must be performed within 30 min after the initial ECG, and the average of these three consecutive results for QTcF will be used to determine eligibility.",
            "criterions": [
                {
                    "exact_snippets": "a single ECG shows a QTcF with an absolute value > 500 ms",
                    "criterion": "QTcF interval",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 500,
                                "unit": "ms"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "the average of these three consecutive results for QTcF will be used to determine eligibility",
                    "criterion": "average QTcF interval (from three ECGs)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "used to determine eligibility"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For the Guardant360 Liquid Biopsy amplification must be at least (++) or (+++) for to meet eligibility.",
            "criterions": [
                {
                    "exact_snippets": "Guardant360 Liquid Biopsy amplification must be at least (++) or (+++)",
                    "criterion": "Guardant360 Liquid Biopsy amplification",
                    "requirements": [
                        {
                            "requirement_type": "amplification level",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "plus signs (++)"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have maximum age of 99 Years",
            "criterions": [
                {
                    "exact_snippets": "maximum age of 99 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 99,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must be MALE",
            "criterions": [
                {
                    "exact_snippets": "Must be MALE",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Abdominal fistula, GI perforation, bowel obstruction, or intra-abdominal abscess within 6 months before first dose.",
            "criterions": [
                {
                    "exact_snippets": "Abdominal fistula ... within 6 months before first dose.",
                    "criterion": "abdominal fistula",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "GI perforation ... within 6 months before first dose.",
                    "criterion": "gastrointestinal perforation",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "bowel obstruction ... within 6 months before first dose.",
                    "criterion": "bowel obstruction",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "intra-abdominal abscess within 6 months before first dose.",
                    "criterion": "intra-abdominal abscess",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Clinically significant hematuria, hematemesis, or hemoptysis of > 0.5 teaspoon (2.5 mL) of red blood, or other history of significant bleeding (e.g., pulmonary hemorrhage) within 12 weeks before first dose.",
            "criterions": [
                {
                    "exact_snippets": "Clinically significant hematuria",
                    "criterion": "hematuria",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Clinically significant ... hematemesis",
                    "criterion": "hematemesis",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Clinically significant ... hemoptysis of > 0.5 teaspoon (2.5 mL) of red blood",
                    "criterion": "hemoptysis",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2.5,
                                "unit": "mL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "other history of significant bleeding (e.g., pulmonary hemorrhage) within 12 weeks before first dose",
                    "criterion": "significant bleeding",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": "within 12 weeks before first dose"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For the FoundationOneLiquid assay, amplification will be eligible. Reports that have an \"equivocal\" or \"subclonal\" designation will not be eligible.",
            "criterions": [
                {
                    "exact_snippets": "For the FoundationOneLiquid assay, amplification will be eligible.",
                    "criterion": "amplification (FoundationOneLiquid assay)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Reports that have an \"equivocal\" or \"subclonal\" designation will not be eligible.",
                    "criterion": "report designation",
                    "requirements": [
                        {
                            "requirement_type": "designation",
                            "expected_value": {
                                "operator": "!=",
                                "value": 1,
                                "unit": "equivocal or subclonal"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Corrected QT interval calculated by the Fridericia formula (QTcF) > 500 ms per electrocardiogram (ECG) within 28 days before first dose of study treatment [add reference for Fridericia formula].",
            "criterions": [
                {
                    "exact_snippets": "Corrected QT interval calculated by the Fridericia formula (QTcF) > 500 ms per electrocardiogram (ECG) within 28 days before first dose of study treatment",
                    "criterion": "corrected QT interval (QTcF)",
                    "requirements": [
                        {
                            "requirement_type": "calculation method",
                            "expected_value": "Fridericia formula"
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 500,
                                "unit": "ms"
                            }
                        },
                        {
                            "requirement_type": "measurement method",
                            "expected_value": "electrocardiogram (ECG)"
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": "within 28 days before first dose of study treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "14. Diagnosis of another malignancy within 2 years before first dose of study treatment, except for superficial skin cancers, or localized, low-grade tumors deemed cured and not treated with systemic therapy.",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of another malignancy within 2 years before first dose of study treatment",
                    "criterion": "diagnosis of another malignancy",
                    "requirements": [
                        {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "timing relative to study treatment",
                            "expected_value": "before first dose"
                        }
                    ]
                },
                {
                    "exact_snippets": "except for superficial skin cancers",
                    "criterion": "superficial skin cancers",
                    "requirements": [
                        {
                            "requirement_type": "exception",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "localized, low-grade tumors deemed cured and not treated with systemic therapy",
                    "criterion": "localized, low-grade tumors",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "deemed cured"
                        },
                        {
                            "requirement_type": "treatment",
                            "expected_value": "not treated with systemic therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Patients who do not meet molecular eligibility criteria will be allowed to enroll if they have liver metastases that meet RECIST criteria for measurable disease. Patients with prostate adenocarcinoma or Neuroendocrine prostate cancer (NEPC) will be allowed to enroll.",
            "criterions": [
                {
                    "exact_snippets": "do not meet molecular eligibility criteria",
                    "criterion": "molecular eligibility criteria",
                    "requirements": [
                        {
                            "requirement_type": "meeting criteria",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "liver metastases that meet RECIST criteria for measurable disease",
                    "criterion": "liver metastases",
                    "requirements": [
                        {
                            "requirement_type": "RECIST measurable disease",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "prostate adenocarcinoma",
                    "criterion": "prostate adenocarcinoma",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Neuroendocrine prostate cancer (NEPC)",
                    "criterion": "Neuroendocrine prostate cancer (NEPC)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. DNA sequencing of a metastatic tumor biopsy specimen showing gene amplification or activating mutation using a CLIA-certified assay. Tumor tissue samples must have been collected within 6 months of enrollment.",
            "criterions": [
                {
                    "exact_snippets": "DNA sequencing of a metastatic tumor biopsy specimen showing gene amplification or activating mutation",
                    "criterion": "metastatic tumor biopsy specimen",
                    "requirements": [
                        {
                            "requirement_type": "DNA sequencing result",
                            "expected_value": [
                                "gene amplification",
                                "activating mutation"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "using a CLIA-certified assay",
                    "criterion": "assay certification",
                    "requirements": [
                        {
                            "requirement_type": "certification",
                            "expected_value": "CLIA-certified"
                        }
                    ]
                },
                {
                    "exact_snippets": "Tumor tissue samples must have been collected within 6 months of enrollment",
                    "criterion": "tumor tissue sample collection time",
                    "requirements": [
                        {
                            "requirement_type": "collection time",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* The subject has evidence of tumor invading the GI tract, active peptic ulcer disease, inflammatory bowel disease (e.g., Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, acute pancreatitis, acute obstruction of the pancreatic duct or common bile duct, or gastric outlet obstruction.",
            "criterions": [
                {
                    "exact_snippets": "evidence of tumor invading the GI tract",
                    "criterion": "tumor invasion of GI tract",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "active peptic ulcer disease",
                    "criterion": "peptic ulcer disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "inflammatory bowel disease (e.g., Crohn's disease)",
                    "criterion": "inflammatory bowel disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "diverticulitis",
                    "criterion": "diverticulitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "cholecystitis",
                    "criterion": "cholecystitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "symptomatic cholangitis",
                    "criterion": "cholangitis",
                    "requirements": [
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "appendicitis",
                    "criterion": "appendicitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "acute pancreatitis",
                    "criterion": "pancreatitis",
                    "requirements": [
                        {
                            "requirement_type": "acuteness",
                            "expected_value": "acute"
                        }
                    ]
                },
                {
                    "exact_snippets": "acute obstruction of the pancreatic duct or common bile duct",
                    "criterion": "obstruction of pancreatic duct or common bile duct",
                    "requirements": [
                        {
                            "requirement_type": "acuteness",
                            "expected_value": "acute"
                        }
                    ]
                },
                {
                    "exact_snippets": "gastric outlet obstruction",
                    "criterion": "gastric outlet obstruction",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. CLIA-certified commercial cell free DNA assay reporting gene amplification or activating mutation within 3 months of enrollment.",
            "criterions": [
                {
                    "exact_snippets": "CLIA-certified commercial cell free DNA assay reporting gene amplification or activating mutation within 3 months of enrollment",
                    "criterion": "cell free DNA assay",
                    "requirements": [
                        {
                            "requirement_type": "certification",
                            "expected_value": "CLIA-certified"
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": "commercial"
                        },
                        {
                            "requirement_type": "reporting",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "analyte",
                            "expected_value": "cell free DNA"
                        }
                    ]
                },
                {
                    "exact_snippets": "reporting gene amplification or activating mutation",
                    "criterion": "gene alteration",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "amplification",
                                "activating mutation"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "within 3 months of enrollment",
                    "criterion": "cell free DNA assay timing",
                    "requirements": [
                        {
                            "requirement_type": "time since assay",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "To be eligible, a patient's tumor must have evidence of gene amplification, an activating mutation, or overexpression of one of the following genes: MET, KIT, RET, VEGFR-1, VEGFR-2, VEGFR-3, FLT3, AXL, TRKB, or TIE2. Eligibility can be met via the following diagnostic tests:",
            "criterions": [
                {
                    "exact_snippets": "tumor must have evidence of gene amplification ... one of the following genes: MET, KIT, RET, VEGFR-1, VEGFR-2, VEGFR-3, FLT3, AXL, TRKB, or TIE2",
                    "criterion": "tumor gene amplification",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "gene",
                            "expected_value": [
                                "MET",
                                "KIT",
                                "RET",
                                "VEGFR-1",
                                "VEGFR-2",
                                "VEGFR-3",
                                "FLT3",
                                "AXL",
                                "TRKB",
                                "TIE2"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "tumor must have evidence of ... activating mutation ... one of the following genes: MET, KIT, RET, VEGFR-1, VEGFR-2, VEGFR-3, FLT3, AXL, TRKB, or TIE2",
                    "criterion": "tumor activating mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "gene",
                            "expected_value": [
                                "MET",
                                "KIT",
                                "RET",
                                "VEGFR-1",
                                "VEGFR-2",
                                "VEGFR-3",
                                "FLT3",
                                "AXL",
                                "TRKB",
                                "TIE2"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "tumor must have evidence of ... overexpression ... one of the following genes: MET, KIT, RET, VEGFR-1, VEGFR-2, VEGFR-3, FLT3, AXL, TRKB, or TIE2",
                    "criterion": "tumor gene overexpression",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "gene",
                            "expected_value": [
                                "MET",
                                "KIT",
                                "RET",
                                "VEGFR-1",
                                "VEGFR-2",
                                "VEGFR-3",
                                "FLT3",
                                "AXL",
                                "TRKB",
                                "TIE2"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Stroke (including transient ischemic attack [TIA]), myocardial infarction (MI), or other ischemic event, or thromboembolic event (e.g. deep venous thrombosis, pulmonary embolism) within 6 months before first dose.",
            "criterions": [
                {
                    "exact_snippets": "Stroke (including transient ischemic attack [TIA]) ... within 6 months before first dose.",
                    "criterion": "stroke (including transient ischemic attack [TIA])",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months before first dose"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "myocardial infarction (MI) ... within 6 months before first dose.",
                    "criterion": "myocardial infarction (MI)",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months before first dose"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "other ischemic event ... within 6 months before first dose.",
                    "criterion": "other ischemic event",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months before first dose"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "thromboembolic event (e.g. deep venous thrombosis, pulmonary embolism) ... within 6 months before first dose.",
                    "criterion": "thromboembolic event (e.g. deep venous thrombosis, pulmonary embolism)",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months before first dose"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Any non-CLIA certified assay such as RNA expression profiling of a metastatic tumor biopsy specimen showing overexpression must be confirmed by a CLIA-certified assay (i.e., immunohistochemistry showing 2+ or 3+ protein expression)",
            "criterions": [
                {
                    "exact_snippets": "non-CLIA certified assay such as RNA expression profiling of a metastatic tumor biopsy specimen showing overexpression must be confirmed by a CLIA-certified assay (i.e., immunohistochemistry showing 2+ or 3+ protein expression)",
                    "criterion": "RNA expression profiling of a metastatic tumor biopsy specimen",
                    "requirements": [
                        {
                            "requirement_type": "overexpression",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "CLIA-certified assay (immunohistochemistry showing 2+ or 3+ protein expression)"
                        }
                    ]
                },
                {
                    "exact_snippets": "immunohistochemistry showing 2+ or 3+ protein expression",
                    "criterion": "protein expression by immunohistochemistry",
                    "requirements": [
                        {
                            "requirement_type": "expression level",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "+"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serious non-healing wound/ulcer/bone fracture.",
            "criterions": [
                {
                    "exact_snippets": "Serious non-healing wound",
                    "criterion": "wound",
                    "requirements": [
                        {
                            "requirement_type": "healing status",
                            "expected_value": "serious non-healing"
                        }
                    ]
                },
                {
                    "exact_snippets": "Serious non-healing ... ulcer",
                    "criterion": "ulcer",
                    "requirements": [
                        {
                            "requirement_type": "healing status",
                            "expected_value": "serious non-healing"
                        }
                    ]
                },
                {
                    "exact_snippets": "Serious non-healing ... bone fracture",
                    "criterion": "bone fracture",
                    "requirements": [
                        {
                            "requirement_type": "healing status",
                            "expected_value": "serious non-healing"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Protein overexpression in a metastatic tumor biopsy specimen determined by immunohistochemistry (IHC) showing 2+ or 3+ protein expression using a CLIA-certified assay.These include common in-house KIT and commercial reference labs for panTRK (e.g. NeoGenomics) and cMET (e.g. NeoGenomics, Caris, Mayo Clinic).",
            "criterions": [
                {
                    "exact_snippets": "Protein overexpression in a metastatic tumor biopsy specimen determined by immunohistochemistry (IHC) showing 2+ or 3+ protein expression using a CLIA-certified assay",
                    "criterion": "protein expression in metastatic tumor biopsy",
                    "requirements": [
                        {
                            "requirement_type": "detection_method",
                            "expected_value": "immunohistochemistry (IHC)"
                        },
                        {
                            "requirement_type": "expression_level",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "+"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "+"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "assay_certification",
                            "expected_value": "CLIA-certified"
                        }
                    ]
                },
                {
                    "exact_snippets": "These include common in-house KIT and commercial reference labs for panTRK (e.g. NeoGenomics) and cMET (e.g. NeoGenomics, Caris, Mayo Clinic)",
                    "criterion": "protein tested",
                    "requirements": [
                        {
                            "requirement_type": "protein",
                            "expected_value": [
                                "KIT",
                                "panTRK",
                                "cMET"
                            ]
                        },
                        {
                            "requirement_type": "testing_lab",
                            "expected_value": [
                                "in-house",
                                "NeoGenomics",
                                "Caris",
                                "Mayo Clinic"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks prior to first dose of study treatment after radiotherapy or at least 4 weeks prior to first dose of study treatment after major surgery (e.g., removal or biopsy of brain metastasis). Subjects must have complete wound healing from major surgery or minor surgery before first dose of study treatment. Eligible subjects must be neurologically asymptomatic and without corticosteroid treatment for neurological indications at the time of first dose of study treatment.",
            "criterions": [
                {
                    "exact_snippets": "Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks prior to first dose of study treatment after radiotherapy or at least 4 weeks prior to first dose of study treatment after major surgery (e.g., removal or biopsy of brain metastasis)",
                    "criterion": "brain metastases or cranial epidural disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment",
                            "expected_value": [
                                "radiotherapy",
                                "surgery",
                                "radiosurgery"
                            ]
                        },
                        {
                            "requirement_type": "stability_duration_after_treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "stability_duration_after_major_surgery",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects must have complete wound healing from major surgery or minor surgery before first dose of study treatment",
                    "criterion": "wound healing from surgery",
                    "requirements": [
                        {
                            "requirement_type": "completeness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Eligible subjects must be neurologically asymptomatic",
                    "criterion": "neurological symptoms",
                    "requirements": [
                        {
                            "requirement_type": "asymptomatic",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "without corticosteroid treatment for neurological indications at the time of first dose of study treatment",
                    "criterion": "corticosteroid treatment for neurological indications",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Major surgery (e.g., GI surgery, removal or biopsy of brain metastasis) within 8 weeks before first dose of study treatment. Complete wound healing from major surgery must have occurred 1 month before first dose and from minor surgery (e.g. simple excision, tooth extraction) at least 10 days before first dose. Subjects with clinically relevant ongoing complications from prior surgery are not eligible.",
            "criterions": [
                {
                    "exact_snippets": "Major surgery (e.g., GI surgery, removal or biopsy of brain metastasis) within 8 weeks before first dose of study treatment",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since surgery",
                            "expected_value": {
                                "operator": ">=",
                                "value": 8,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Complete wound healing from major surgery must have occurred 1 month before first dose",
                    "criterion": "wound healing from major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since wound healing",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "month"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "from minor surgery (e.g. simple excision, tooth extraction) at least 10 days before first dose",
                    "criterion": "minor surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since surgery",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects with clinically relevant ongoing complications from prior surgery are not eligible",
                    "criterion": "clinically relevant ongoing complications from prior surgery",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* DNA sequencing of metastatic tumor biopsy specimen or cfDNA test",
            "criterions": [
                {
                    "exact_snippets": "DNA sequencing of metastatic tumor biopsy specimen",
                    "criterion": "metastatic tumor biopsy specimen",
                    "requirements": [
                        {
                            "requirement_type": "DNA sequencing performed",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "cfDNA test",
                    "criterion": "cfDNA test",
                    "requirements": [
                        {
                            "requirement_type": "test performed",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "Inclusion Criteria",
            "criterions": []
        },
        {
            "line": "5. Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 4 weeks before first dose of study treatment. Systemic treatment with radionuclides within 6 weeks before the first dose of study treatment. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible.",
            "criterions": [
                {
                    "exact_snippets": "Radiation therapy for bone metastasis within 2 weeks before first dose of study treatment",
                    "criterion": "radiation therapy for bone metastasis",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "any other radiation therapy within 4 weeks before first dose of study treatment",
                    "criterion": "other radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Systemic treatment with radionuclides within 6 weeks before the first dose of study treatment",
                    "criterion": "systemic treatment with radionuclides",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible",
                    "criterion": "clinically relevant ongoing complications from prior radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}